Provided by Tiger Fintech (Singapore) Pte. Ltd.

Disc Medicine

51.68
+0.07000.14%
Post-market: 51.680.00000.00%16:20 EDT
Volume:288.30K
Turnover:14.63M
Market Cap:1.79B
PE:-13.19
High:51.81
Open:51.61
Low:49.73
Close:51.61
Loading ...

Disc Medicine Q1 EPS $(1.02), Inline

Benzinga
·
07 May

Disc Medicine Inc. Launches APOLLO Trial for Bitopertin in Treatment of Erythropoietic Protoporphyria

Reuters
·
07 May

Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update

THOMSON REUTERS
·
07 May

Disc Medicine Q1 Net Income USD -34.085 Million VS. Ibes Estimate USD -34.3 Million

THOMSON REUTERS
·
07 May

Press Release: Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update

Dow Jones
·
07 May

Press Release: CHAMPION IRON REPORTS ITS FY2025 FOURTH QUARTER PRODUCTION AND SALES

Dow Jones
·
30 Apr

Insider Shake-Up: Disc Medicine Directors Make Major Stock Moves!

TIPRANKS
·
27 Mar

With 65% ownership, Disc Medicine, Inc. (NASDAQ:IRON) boasts of strong institutional backing

Simply Wall St.
·
23 Mar

Victoria's Secret, Bitdeer, and More Stocks See Activist Action -- Barrons.com

Dow Jones
·
22 Mar

Disc Medicine Is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
18 Mar

Disc Medicine price target raised to $132 from $99 at Cantor Fitzgerald

TIPRANKS
·
18 Mar

Disc Medicine (IRON) Gets a Buy from Cantor Fitzgerald

TIPRANKS
·
18 Mar

All You Need to Know About Disc Medicine, Inc. (IRON) Rating Upgrade to Buy

Zacks
·
15 Mar

Disc Medicine Coverage Assumed by Morgan Stanley at Overweight

Dow Jones
·
08 Mar

Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI), Disc Medicine (IRON) and PTC Therapeutics (PTCT)

TIPRANKS
·
07 Mar

Disc Medicine Is Maintained at Sector Outperform by Scotiabank

Dow Jones
·
03 Mar

Wall Street Analysts Predict a 68.78% Upside in Disc Medicine, Inc. (IRON): Here's What You Should Know

Zacks
·
03 Mar

Disc Medicine price target raised to $75 from $73 at Scotiabank

TIPRANKS
·
03 Mar

Promising Prospects for Disc Medicine: Buy Rating Backed by Bitopertin’s Potential and Strong Financial Health

TIPRANKS
·
28 Feb

Disc Medicine’s 2024 Financial Results and Clinical Progress

TIPRANKS
·
28 Feb